Bioavailability of Fatty Acids From Krill Oil and Krill Meal and Fatty Acids From Fish Oil in Healthy Subjects.

Randomized, Single-center, Open-label, Blinded Endpoint Assessment Study (Cross-over Study With 3 Study Products) on Bioavailability of Fatty Acids (Plasma Lipid Fractions) From Krill Oil and Krill Meal and Fatty Acids From Fish Oil in Healthy Subjects.

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02089165

Acronym

RISU

Enrollment

Registered

2014-03-17

Start date

2014-02-28

Completion date

2014-05-31

Last updated

2014-06-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy

Brief summary

The purpose of the study is to compare the acute bioavailability of two different krill oil products called krill oil and krill meal in comparison to fish oil product.

Interventions

DIETARY_SUPPLEMENTKrill oil

Krill oil from Antarctic krill, per oral, capsule, targeted daily n-3 PUFA dose of 1 700 mg, single administration

DIETARY_SUPPLEMENTKrill meal

Krill meal, granular meal from Antarctic krill, per oral, targeted daily n-3 PUFA dose of 1 700 mg, single administration

DIETARY_SUPPLEMENTFish oil

Fish oil, per oral, capsule, targeted daily n-3 PUFA dose of 1 700 mg, single administration

Study design

Allocation

RANDOMIZED

Intervention model

CROSSOVER

Primary purpose

TREATMENT

Masking

SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

18 Years to 65 Years

Healthy volunteers

Yes

Inclusion criteria

* Healthy female and male * Age 18 - 65 years * Body mass index 18.5 - 30 * Informed consent, signed

Exclusion criteria

* Medication potential to affect the bioavailability of fatty acids (e.g. lipid-lowering drugs) * Familial hypercholesterolemia, marked combined hyperlipidemia, condition that would impair, fat absorption (e.g. chronic pancreatitis, pancreatic lipase deficiency syndrome) * Any untreated medical condition affecting absorption of fat * Type 1 and 2 diabetes * Cancer or other malignant disease within past five years * Periodical hormone replacement therapy * High intake of oily fish (once a week or more) (i.e. salmon, herring, sardines, mackerel, vendace) * Smoking * Alcohol consumption \> 15 doses per week * Females who are pregnant, breast-feeding or intend to become pregnant * Hypersensitivity to any of the components of the test product * Regular use of n-3 supplements 4 weeks before randomization * Lack of suitability for participation in the trial, for any medical reason, as judged by the principal investigator

Design outcomes

Primary

Measure	Time frame
Incremental 0-72 h area under the curve of EPA + DHA proportion in plasma phospholipids.	0-72 h

Secondary

Measure	Time frame
Incremental 0-72 h area under the curve of EPA + DHA proportion in plasma triglyceride.	0-72 h

Other

Measure	Time frame
Mean proportions of fatty acids in plasma phospholipids and triglycerides.	0-72 h

Countries

Finland

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 18, 2026